Sareum Holdings plc (LON:SAR) Insider Buys £10,083.96 in Stock

Sareum Holdings plc (LON:SAR) insider Stephen Parker purchased 84,033 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of GBX 12 ($0.16) per share, for a total transaction of £10,083.96 ($13,051.98).

Sareum Stock Performance

Sareum stock opened at GBX 13.44 ($0.17) on Friday. The firm has a market cap of £16.79 million, a PE ratio of -3.18 and a beta of -1.08. Sareum Holdings plc has a twelve month low of GBX 10.03 ($0.13) and a twelve month high of GBX 52.50 ($0.68). The firm’s 50 day moving average price is GBX 17.47 and its two-hundred day moving average price is GBX 23.

Sareum (LON:SAR) last posted its earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter. Equities analysts anticipate that Sareum Holdings plc will post -3.8 EPS for the current fiscal year.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.